2016 American Transplant Congress
Graft Versus Host Disease (GVHD) in Patients with Pancreas Transplant Alone (PTA).
GVHD is rare after kidney-pancreas transplant with 18 case reports to date and never been described in the setting of PTA.We share our experience.Patient A:…2016 American Transplant Congress
Recapitulating Peripheral T Cell Development in Neonatal Mice to Induce Transplant Tolerance.
University of Alberta, Edmonton, Canada.
Purpose: Neonatal mice are susceptible to tolerance induction with semi-allogeneic bone marrow and spleen cells (BMC/SC) while allogeneic BMC/SC cause acute lethal graft-versus-host disease (GVHD).…2016 American Transplant Congress
Dynamic Detection of Anti-HLA Antibodies Can Predict aGVHD and OS in HLA-12/12 Matched Unrelated-Donor Allo-HSCT for Hematological Malignancies.
The NMDP and CIBMTR provided guidelines for the use of anti-HLA antibodies in unrelated-donors hematopoietic stem cell transplantation (HSCT). However, a deeper understanding of other…2016 American Transplant Congress
CD8+TCR– Facilitating Cells in Mobilized Peripheral Blood Mononuclear Cells Are Enriched with IL-10 Producing B Cells.
Institute for Cellular Therapeutics, University of Louisville, Louisville, KY.
We recently reported that facilitating cell (FC) enriched hematopoietic progenitor stem cell (HSPC) allografts (FCRx) induced tolerance without graft-versus-host disease (GVHD) or engraftment syndrome in…2016 American Transplant Congress
Absence of Host CD137 Signaling Converts Chronic GVHD Toward Acute GVHD.
CD137 functions mainly as a costimulatory molecule for T cell activation. However, its functions have been found in a variety of other immune and nonimmune…2016 American Transplant Congress
Nontuberculous Mycobacterial Infection Among Allogeneic Hematopoietic Stem Cell Transplant Recipients: A 16-Year Cohort Study.
University Health Network, Toronto, Canada.
Background: Nontuberculous mycobacteria (NTM) infections in hematopoietic stem cell transplant (HSCT) recipients can be associated with significant morbidity and mortality.Methods: We identified all allogeneic HSCT…2016 American Transplant Congress
Seven Year Follow-Up of a Phase 2 Clinical Trial to Induce Tolerance in Living Donor Renal Transplant Recipients.
1Northwestern University, Chicago; 2University of Louisville, Louisville.
36 subjects have been enrolled and 31 transplanted in a phase 2 protocol (IDE 13947) to induce tolerance in recipients of living donor renal allografts…2016 American Transplant Congress
Direct IL-33 Stimulation of T Regulatory Cells via Suppression of Tumorigenicity 2 (ST2) Is Required for Effective Control of Alloimmune Responses.
Background: IL-33 is a pleotropic cytokine that can protect against cardiac transplant rejection by expanding regulatory T cells (Treg), particularly a Treg subset expressing the…2016 American Transplant Congress
Combination of Veto Cell Transfer and iNKT Cell Therapy Establishes Complete Hematopoietic Chimerism in Non-Myeloablative BMT Recipients.
Hematopoietic chimerism after non-myeloablative bone marrow transplantation (nmBMT) has been found beneficial for establishment of transplant tolerance. Since bone marrow cells (BMCs) are endowed with…2016 American Transplant Congress
Administration of IL-33 Before Allogeneic Stem Cell Transplantation Expands Recipient Treg That Prevent Graft- vs. Host Disease.
Background: During allogeneic hematopoietic cell transplantation (alloHCT), non-hematopoietic cell IL-33 is augmented and released by recipient conditioning to promote Type 1 alloimmunity and lethal acute…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- Next Page »